Navigation Links
Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
Date:8/5/2008

the CD4 receptor found on both effector and regulatory T cells. MTRX1011A is designed to block the activation and function of T effector cells and to favor dominance of T regulatory cells. This unique mechanism of action has the potential to ameliorate autoimmune disease symptoms not only through its direct action on pathogenic CD4 T cells, but by impacting downstream effects of CD4 T cells such as B cell autoantibody production.

About Tolerx

In addition to the anti-CD4 monoclonal antibody program, Tolerx is currently developing otelixizumab, an anti-CD3 monoclonal antibody, for the treatment of autoimmune disease, specifically, type 1 diabetes with its collaboration partner, GlaxoSmithKline. Tolerx is also engaged in preclinical development of new monoclonal antibody product candidates that engage the body's immune system and promote and enhance immune responses. These antibodies are being assessed for potential benefit in the treatment of cancer, chronic viral diseases, and as an adjunct to vaccines. For more information, please visit http://www.tolerx.com.

Safe Harbor Statement

This press release contains certain statements that are preceded by, followed by, or that include the words "look forward," "will receive," "is expected to," "may have," "potential benefit" or similar expressions or the negation thereof. Such statements, which are not historical facts, constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Statements regarding Genentech's activities with respect to further development of MTRX1011A, the realization by Tolerx of any additional payments related to MTRX1011A and the anticipated clinical progress and development of MTRX1011A are all forward-looking statements. Such forward-looking statements involve risks, uncertainties and other factors that may cause the actual performance or achievements of Tolerx to be m
'/>"/>

SOURCE Tolerx, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
2. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
3. Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
4. Cara Therapeutics Announces Successful Completion of Phase I Clinical Trial of Novel Analgesic, CR845
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. Emisphere Announces Recruitment of Novartis Phase III Study for Oral Osteoporosis Treatment
7. Amicus Therapeutics Announces Successful Completion of End of Phase 2 Meeting With FDA for Amigal in Fabry Disease
8. Anpath Group, Inc. Announces Approval of its Disinfectant by the State of Florida
9. Peptimmune Announces Grant of United States Patent for PI-2301 Peptide Copolymer for Multiple Sclerosis
10. Nile Therapeutics Announces Dosing in Second Phase Ib Study of CD-NP in Heart Failure Patients
11. Wound Management Technologies, Inc. Announces Agreement for Evidence Based Study for Diabetic Venous Ulcers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014 NxStage Medical, Inc. (NASDAQ: ... innovative dialysis products, announced today that the U.S. ... System One™ to perform hemodialysis overnight while the ... nocturnal hemodialysis. NxStage,s® System One is the first ... for this indication. Home nocturnal ...
(Date:12/22/2014)... , Dec. 22, 2014 Research and Markets ... of the "US Self-monitoring Blood Glucose Market" ... http://photos.prnewswire.com/prnh/20130307/600769 This market insight focuses on ... the United States . Reimbursement analysis ... Thorough product analyses for more than 73 SMBG meters ...
(Date:12/22/2014)... 2014 Research and Markets ( ... "Investment Analysis of the US Medical Device ... http://photos.prnewswire.com/prnh/20130307/600769 ... device sector identifies the key trends and rationale ... and mergers and acquisitions. The study ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3US Self-monitoring Blood Glucose Market 2Investment Analysis of the US Medical Device Sector 2
... 4 Phosphagenics,Limited (ASX: POH, AIM: PSG, OTCQX: ... will jointly commence a phase 2 human clinical,trial ... Phospha E(R),in the management of metabolic syndrome. ... double-blind phase 2,clinical trial, which will commence shortly. ...
... Ore., Oct. 3 Virogenomics, Inc. today,announced that ... grant from the,National Institute of Standards and Technology ... that tests for many different biological markers in,a ... could revolutionize research on and,the diagnosis of multifactorial ...
Cached Medicine Technology:Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 2Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 3Nestle Nutrition and Phosphagenics to Commence Phospha E(R) Phase 2 Clinical Trial 4Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 2Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 3Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors 4
(Date:12/25/2014)... Recently, iFitDress.com, the popular online supplier of wedding ... new selection of black one-shoulder cocktail dresses . In ... are available at discounted prices, up to 70% off. ... for three weeks only. You know, we have thousands of ... in our new items can visit our website for more ...
(Date:12/25/2014)... 2014 The short film “Color of Honor” ... honor of a true 9/11 hero, Welles Remy Crowther. It ... the 24 hours of Nuremberg International Short Film Festival and ... Actress, screenwriter and director Luciana Lagana plays the ... with her husband, Gregory Graham - Graham plays ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Miami, FL (PRWEB) December 25, 2014 When ... often find themselves in a frenzy to get rid of ... classroom. But families in Coral Gables now have the solution ... its second salon clinic location, Lice Troopers provides full spectrum ... in the Coral Gable area, including Sunset, Key Biscayne, Brickell, ...
(Date:12/25/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, 2014 (HealthDay ... receive effective, less expensive care from a clinic that functions ... of dedicated health care professionals, a new study shows. ... either hospitalization or a trip to the emergency room when ... the University of Texas in Houston versus usual care, according ...
Breaking Medicine News(10 mins):Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 2Health News:Coordinated Care Through 'Medical Home' Best for Chronically Ill Kids: Study 3
... In this News Digest:, Summary of a study being published ... finding that close relatives of women who carry mutations in ... genetic mutations -- do not have an increased risk of developing ... do not have such mutations. These results run counter to a ...
... , MONDAY, Oct. 31 (HealthDay News) -- People with ... disabled and less likely to return home than stroke patients ... looked at 702 people who had dementia at the time ... had a stroke. The stroke patients with pre-existing dementia ...
... - An unprecedented decade of economic demise and a population ... putting Michigan in a precarious spot: More aging residents needing ... Add in a steady decline in elderly support ratio ... and the situation becomes more dire. But with the help ...
... Men with prostate cancer are twice as likely to commit ... words may reduce this risk, reveals research at the Sahlgrenska ... a study at the University of Gothenburg,s Sahlgrenska Academy, researchers ... surgery for prostate cancer. The suicide rate in this group ...
... Oct. 31 (HealthDay News) --,The longer they live in the ... will develop health problems, a new study says. Researchers ... Examination Survey and discovered a dramatic increase in obesity, diabetes ... the United States for more than 20 years. Compared ...
... liberal in their advice to patients on alcohol consumption. ... while men who are heavy drinkers get to continue ... a thesis from the Sahlgrenska Academy at the University ... Gothenburg,s Sahlgrenska Academy have for the first time looked ...
Cached Medicine News:Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 2Health News:Study shows no increased risk of breast cancer for non-carriers in families with BRCA gene mutation 3Health News:Dementia May Impede Stroke Recovery 2Health News:Michigan State University tackles health needs of an aging statewide population 2Health News:New findings could lower risk of suicide in men with prostate cancer 2Health News:Life in U.S. Not Always a Plus for Immigrants' Health 2Health News:Doctors' own alcohol consumption colors advice to patients 2
A highly precise stereotactic radiosurgery system for the treatment of intra-cranial lesions....
The Primus linear accelerator is a fully digital, technologically advanced radiation therapy treatment delivery system. It can be configured for delivery of routine, 3-D conformal or IMRT treatments....
... The cost-effective, proven and reliable ... rates for rapid patient treatment, fastest ... flatness - less than 500 milliseconds, ... highest beam stability, greatest number of ...
The Clinac 2100 C/D family of accelerators are reliable, easy-to-use, flexible and cost-effective systems....
Medicine Products: